Örjan Åkerborg

449 total citations
23 papers, 307 citations indexed

About

Örjan Åkerborg is a scholar working on Economics and Econometrics, Molecular Biology and Genetics. According to data from OpenAlex, Örjan Åkerborg has authored 23 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Economics and Econometrics, 6 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Örjan Åkerborg's work include Health Systems, Economic Evaluations, Quality of Life (7 papers), Atrial Fibrillation Management and Outcomes (4 papers) and Cardiac Arrhythmias and Treatments (3 papers). Örjan Åkerborg is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (7 papers), Atrial Fibrillation Management and Outcomes (4 papers) and Cardiac Arrhythmias and Treatments (3 papers). Örjan Åkerborg collaborates with scholars based in Sweden, United States and France. Örjan Åkerborg's co-authors include Jens Lagergren, Bengt Sennblad, Lars Arvestad, Pelin Sahlén, Anders Sköldunger, Mats Rosenlund, Anders Wimo, Laura Fratiglioni, Marie Öhman and Daniel Lundin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Bioinformatics.

In The Last Decade

Örjan Åkerborg

21 papers receiving 300 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Örjan Åkerborg Sweden	9	173	90	42	38	28	23	307
Erica Sermijn Belgium	10	137 0.8×	146 1.6×	41 1.0×	28 0.7×	9 0.3×	18	332
Maíra R. Rodrigues Brazil	10	61 0.4×	109 1.2×	11 0.3×	19 0.5×	3 0.1×	20	249
Teresa Lam Australia	11	69 0.4×	54 0.6×	12 0.3×	73 1.9×	23 0.8×	19	270
Circe Tsui United States	9	583 3.4×	378 4.2×	361 8.6×	50 1.3×	32 1.1×	16	930
Fangqin Lin China	11	291 1.7×	148 1.6×	62 1.5×	28 0.7×	15 0.5×	17	512
Mashaal Sohail United States	7	132 0.8×	346 3.8×	13 0.3×	14 0.4×	7 0.3×	14	453
Giordano Bottà United States	8	155 0.9×	81 0.9×	37 0.9×	12 0.3×	32 1.1×	14	349
Raymond Raymond Indonesia	10	43 0.2×	22 0.2×	18 0.4×	22 0.6×	23 0.8×	49	331
B.N. Mukherjee India	15	90 0.5×	329 3.7×	31 0.7×	18 0.5×	17 0.6×	77	617
Jez L. Marston United States	10	135 0.8×	22 0.2×	96 2.3×	23 0.6×	6 0.2×	15	242

Countries citing papers authored by Örjan Åkerborg

Since Specialization

Citations

This map shows the geographic impact of Örjan Åkerborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Örjan Åkerborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Örjan Åkerborg more than expected).

Fields of papers citing papers by Örjan Åkerborg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Örjan Åkerborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Örjan Åkerborg. The network helps show where Örjan Åkerborg may publish in the future.

Co-authorship network of co-authors of Örjan Åkerborg

This figure shows the co-authorship network connecting the top 25 collaborators of Örjan Åkerborg. A scholar is included among the top collaborators of Örjan Åkerborg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Örjan Åkerborg. Örjan Åkerborg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Asahi, Koichi, Tsuneo Konta, Kouichi Tamura, et al.. (2024). The health‐economic impact of urine albumin‐to‐creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation. 16(1). 108–119.

Konta, Tsuneo, Koichi Asahi, Kouichi Tamura, et al.. (2024). The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients. Clinical and Experimental Nephrology. 29(5). 583–595.

Rossing, Peter, Kerstin Folkerts, James Harris, et al.. (2023). Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes. Journal of Medical Economics. 26(1). 935–943. 5 indexed citations

Blankenburg, Michael, et al.. (2023). Economic evaluation of supplemental breast cancer screening modalities to mammography or digital breast tomosynthesis in women with heterogeneously and extremely dense breasts and average or intermediate breast cancer risk in US healthcare. Journal of Medical Economics. 26(1). 850–861. 6 indexed citations

Blomström‐Lundqvist, Carina, Luis A. Garcı́a Rodrı́guez, Örjan Åkerborg, et al.. (2022). Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis. Journal of Medical Economics. 25(1). 1085–1091. 2 indexed citations

Schweikert, Bernd, et al.. (2020). Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. PharmacoEconomics - Open. 4(4). 635–648. 5 indexed citations

Beck, Ekkehard, Véronique Abitbol, Örjan Åkerborg, et al.. (2020). Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England. Vaccine. 38(47). 7558–7568. 19 indexed citations

Dalén, Johan, Ulrika Harmenberg, Magnus Lindskog, et al.. (2019). <p>Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis</p>. Cancer Management and Research. Volume 11. 1289–1297. 5 indexed citations

Åkerborg, Örjan, et al.. (2019). High-Resolution Regulatory Maps Connect Vascular Risk Variants to Disease-Related Pathways. Circulation Genomic and Precision Medicine. 12(3). e002353–e002353. 13 indexed citations

10.

Lindsay, James O., Javier P. Gisbert, Reema Mody, et al.. (2016). PTH-070 A Multinational Study to Determine Indicators of Suboptimal Therapy Among Ulcerative Colitis Patients Treated with Tumour Necrosis Factor Antagonists. A253–A254. 1 indexed citations

11.

Tang, Yuan, Paul Bycott, Örjan Åkerborg, et al.. (2014). Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study. SHILAP Revista de lepidopterología. 1 indexed citations

12.

Åkerborg, Örjan, et al.. (2014). Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study. Cancer Management and Research. 6. 365–365. 2 indexed citations

13.

Höglund, Martin, et al.. (2014). Economic Evaluation of Posaconazole Versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infection in High-Risk Neutropenic Patients in Sweden. Clinical Drug Investigation. 34(7). 483–489. 8 indexed citations

14.

Reynolds, Matthew W., et al.. (2013). Cost-effectiveness of dronedarone and standard of care compared with standard of care alone: US results of an ATHENA lifetime model. ClinicoEconomics and Outcomes Research. 5. 19–19. 3 indexed citations

15.

Lester, J.F., Jason Agulnik, Örjan Åkerborg, et al.. (2013). What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?—Results from the lung cancer economics and outcomes research (LUCEOR) study. Lung Cancer. 82(1). 128–135. 9 indexed citations

16.

Nilsson, Jonas, et al.. (2012). Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation—results for Canada, Italy, Sweden and Switzerland. The European Journal of Health Economics. 14(3). 481–493. 6 indexed citations

17.

Åkerborg, Örjan, et al.. (2012). Cost-Effectiveness of Dronedarone in Atrial Fibrillation: Results for Canada, Italy, Sweden, and Switzerland. Clinical Therapeutics. 34(8). 1788–1802. 10 indexed citations

18.

Åkerborg, Örjan, Daniel Lundin, Bei Wang, et al.. (2010). A computational screen for site selective A-to-I editing detects novel sites in neuron specific Hu proteins. BMC Bioinformatics. 11(1). 6–6. 29 indexed citations

19.

Åkerborg, Örjan, Bengt Sennblad, & Jens Lagergren. (2008). Birth-death prior on phylogeny and speed dating. BMC Evolutionary Biology. 8(1). 77–77. 19 indexed citations

20.

Åkerborg, Örjan. (2008). Taking advantage of phylogenetic trees in comparative genomics. KTH Publication Database DiVA (KTH Royal Institute of Technology). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact